Zentalis(US:ZNTL)2026-03-26 20:24Financial Performance - Zentalis Pharmaceuticals reported a net loss of $137.1 million for the year ended December 31, 2025, compared to a net loss of $165.9 million in 2024, representing a 17.3% decrease in losses [19]. - The net loss per common share for 2025 was $1.91, an improvement from $2.33 in 2024 [19]. - The total operating expenses for 2025 were $152.8 million, down from $258.6 million in 2024, marking a 41% reduction [19]. - The company reported no revenues from licensing and sales of intellectual property in 2025, compared to $67.4 million in 2024 [19]. Research and Development - Research and development expenses decreased to $107.3 million in 2025 from $167.8 million in 2024, a reduction of 64.5 million or 36.1% [12]. - The completion of enrollment for the DENALI Part 2a trial is expected to support dose confirmation in the first half of 2026, with topline results anticipated by year-end 2026 [4]. - The company plans to initiate the Phase 3 ASPENOVA trial in the first half of 2026, comparing azenosertib to standard-of-care chemotherapy for Cyclin E1-positive PROC patients [5]. - Zentalis is also exploring the combination of azenosertib with bevacizumab in the ongoing MUIR study for earlier treatment settings in ovarian cancer [5]. Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $245.9 million, providing a cash runway into late 2027 [5]. Administrative Expenses - General and administrative expenses significantly decreased to $37.7 million in 2025 from $87.1 million in 2024, a decline of 56.7% [12].